You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 8,354,430

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,354,430

Title:	Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine
Abstract:	A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): ##STR00001## optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 19.9.degree., 20.7.degree. and 34.1.degree..+-.0.2.degree. is administered to a patient in need thereof.
Inventor(s):	Raga; Manuel (Barcelona, ES), Sallares; Juan (Barcelona, ES), Guerrero; Marta (Barcelona, ES), Guglietta; Antonio (Molins De Rei, ES), Arrang; Jean-Michel (Dourdan, ES), Schwartz; Jean-Charles (Paris, FR), Stark; Holger (Homburg, DE), Schunack; Walter (Berlin, DE), Ligneau; Xavier (Saint Gregoire, FR), Lecomte; Jeanne-Marie (Paris, FR), Ganellin; Charon (Thame, GB)
Assignee:	Bioprojet (Paris, FR)
Application Number:	13/491,229
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,354,430
Patent Claims:	1. A method for the treatment of sleep apnea, comprising administering crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): ##STR00003## optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 19.9.degree., 20.7.degree. and 34.1.degree..+-.0.2.degree.. 2. The method of claim 1 wherein the crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride according to claim 1 has an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 15.4.degree., 16.3.degree., 16.9.degree., 17.8.degree., 19.9.degree., 20.7.degree., 21.0.degree., 21.8.degree., 22.6.degree., 24.5.degree., 24.6.degree., 25.0.degree., 25.5.degree., 26.3.degree., 28.3.degree., 30.3.degree., 34.1.degree., 35.8.degree., 40.0.degree., 46.0.degree..+-.0.2.degree.. 3. A method for the treatment of diurnal somnolence comprising administering crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): ##STR00004## comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 19.9.degree., 20.7.degree. and 34.1.degree..+-.0.2.degree.. 4. The method of claim 3 wherein the crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride according to claim 1 has an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 15.4.degree., 16.3.degree., 16.9.degree., 17.8.degree., 19.9.degree., 20.7.degree., 21.0.degree., 21.8.degree., 22.6.degree., 24.5.degree., 24.6.degree., 25.0.degree., 25.5.degree., 26.3.degree., 28.3.degree., 30.3.degree., 34.1.degree., 35.8.degree., 40.0.degree., 46.0.degree..+-.0.2.degree.. 5. A method for the treatment of psychotropic disorders comprising administering crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): ##STR00005## optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 19.9.degree., 20.7.degree. and 34.1.degree..+-.0.2.degree.. 6. The method of claim 5 wherein the crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride according to claim 1 has an X-ray diffractogram that comprises characteristic peaks (2.theta.) at 11.2.degree., 15.4.degree., 16.3.degree., 16.9.degree., 17.8.degree., 19.9.degree., 20.7.degree., 21.0.degree., 21.8.degree., 22.6.degree., 24.5.degree., 24.6.degree., 25.0.degree., 25.5.degree., 26.3.degree., 28.3.degree., 30.3.degree., 34.1.degree., 35.8.degree., 40.0.degree., 46.0.degree..+-.0.2.degree..

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.